There has been a dramatic increase in the use of randomized phase II cancer clinical trials in recent years because of lower sample size requirements when multiple treatments are being evaluated. This book will cover both the latest developments in methodology as well as traditional single-arm phase II trial methods. The statistical level will be kept fairly low so that the book will be accessible to not only statisticians but clinicians conducting phase II clinical trials as well.